CGTX logo

CGTX
Cognition Therapeutics Inc

3,975
Mkt Cap
$80.83M
Volume
555,017.00
52W High
$3.83
52W Low
$0.2223
PE Ratio
-2.63
CGTX Fundamentals
Price
$0.9046
Prev Close
$0.8602
Open
$0.909
50D MA
$1.03
Beta
1.77
Avg. Volume
1.3M
EPS (Annual)
-$0.3228
P/B
2.35
Rev/Employee
$0.00
$61.87
Loading...
Loading...

About

Cognition Therapeutics, Inc. is a clinical stage neuroscience company which engages in developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. It offers the CT1812 which aims to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration, geographic atrophy and other conditions. The company was founded by Franz F. Hefti, Gilbert M. Rishton, and Susan M. Catalano on August 21, 2007 and is headquartered in Purchase, NY.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
14

Frequently Asked Questions

What is Market Cap of Cognition Therapeutics Inc?
What is the 52-week high for Cognition Therapeutics Inc?
What is the 52-week low for Cognition Therapeutics Inc?
What is Cognition Therapeutics Inc stock price today?
What was Cognition Therapeutics Inc stock price yesterday?
What is the PE ratio of Cognition Therapeutics Inc?
What is the Price-to-Book ratio of Cognition Therapeutics Inc?
What is the 50-day moving average of Cognition Therapeutics Inc?
How many employees does Cognition Therapeutics Inc have?

Latest CGTX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.